RNA-based mechanisms underlying oncogenicity and drug resistance in NRG1-rearranged non-small cell lung cancer
Pathology - Research and Practice · 2026
DOI: 10.1016/j.prp.2025.156323 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Ameeduzzafar Zafar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Al-Jouf 72341, Saudi Arabia. Electronic address: azafar@ju.edu.sa. Hauptthemen laut MEDLINE: Neuregulin-1, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 101 Literaturangaben. Gefördert von: Jouf University.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC), accounting for nearly 85 % of lung tumors, remains one of the most fatal cancers worldwide. Among the various oncogenic drivers identified in NSCLC, neuregulin-1 (NRG1) gene fusions, though rare, occurring in approximately 0.1-0.3 % of cases, are clinically significant, particularly in invasive mucinous adenocarcinomas. These genomic events trigger abnormal heterodimerization of ERBB2 and ERBB3, stimulating downstream PI3K/AKT and MAPK pathways, which in turn foster uncontrolled growth, metastatic potential, and therapeutic resistance. These genomic events cause ERBB2 and ERBB3 to form abnormal heterodimers that activate downstream PI3K/AKT and MAPK signaling pathways, driving uncontrolled growth, metastasis, and therapeutic resistance. Alongside these mechanisms, non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have emerged as pivotal regulators of cancer-related networks. Although they do not encode proteins, ncRNAs exert influence at transcriptional, post-transcriptional, and epigenetic levels, with the capacity to either suppress or enhance oncogenic processes. This review examines the interplay between ncRNA activity and NRG1 fusion-driven signaling in NSCLC, highlighting their roles in modulating pathways and contributing to drug resistance. Tumor-suppressive miRNAs, such as miR-22 and miR-296-5p, directly target NRG1 or ERBB2/ERBB3 transcripts, thereby weakening aberrant signaling cascades. Conversely, oncogenic ncRNAs like MALAT1 and HOTAIR facilitate epithelial-mesenchymal transition, cell proliferation, and chemoresistance, while circRNAs amplify oncogenic effects by acting as miRNA sponges. Collectively, these regulatory molecules shape the oncogenic landscape of NRG1-rearranged NSCLC and influence therapeutic outcomes. Dysregulated ncRNAs thus hold promise as biomarkers for diagnosis, prognosis, and treatment planning, with therapeutic strategies aimed at restoring tumor-suppressive ncRNAs or inhibiting oncogenic ones offering a potential avenue to overcome resistance in this subset of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Al-Jouf 72341, Saudi Arabia. Electronic address: azafar@ju.edu.sa.
- Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Al-Jouf 72341, Saudi Arabia.
- Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
- Center for Health Research, Northern Border University, Arar, Saudi Arabia.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Baha University, Al-Baha 65779, Saudi Arabia.
- Department of Pharmacy, College of Health Sciences, Arsi University, Asella 396, Ethiopia.
Förderung
- Jouf University
Zitieren
APA
Zafar, A., Alsaidan, O. A., Khalid, M., Mujtaba, M. A., Alquraini, A., & Yasir, M. (2026). RNA-based mechanisms underlying oncogenicity and drug resistance in NRG1-rearranged non-small cell lung cancer. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156323
Vancouver
Zafar A, Alsaidan OA, Khalid M, Mujtaba MA, Alquraini A, Yasir M. RNA-based mechanisms underlying oncogenicity and drug resistance in NRG1-rearranged non-small cell lung cancer. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2025.156323
BibTeX
@article{Zafar2026,
author = {Zafar, Ameeduzzafar and Alsaidan, Omar Awad and Khalid, Mohammad and Mujtaba, Md Ali and Alquraini, Ali and Yasir, Mohd},
title = {RNA-based mechanisms underlying oncogenicity and drug resistance in NRG1-rearranged non-small cell lung cancer},
journal = {Pathology - Research and Practice},
year = {2026},
doi = {10.1016/j.prp.2025.156323}
}
EUVIMED